Diabetes-Induced Birth Defects: What Do We Know? What Can We Do?

被引:51
|
作者
Reece, E. Albert [1 ]
机构
[1] Univ Maryland, Sch Med, Baltimore, MD 21210 USA
关键词
Antioxidant therapy; Birth defects; Fatty acid; Folic acid; Diabetic embryopathy; Dietary supplementation; Hyperglycemia; Infant mortality; Pregnancy; Glucose control; Molecular pathogenesis; Preconception care; Diabetes; INOSITOL POLYPHOSPHATES; CONGENITAL-ANOMALIES; SUPEROXIDE-DISMUTASE; INSULIN THERAPY; UNITED-STATES; EMBRYOPATHY; PREGNANCY; HYPERGLYCEMIA; PREVENTION; ACTIVATION;
D O I
10.1007/s11892-011-0251-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Birth defects are the leading cause of infant mortality in the United States, which has one of the highest infant mortality rates in the developed world. Many of these birth defects can be attributed to pre-existing, or pregestational, diabetes in pregnancy, which significantly increases a mother's risk of having a child with a major birth defect. Strict preconceptional and early pregnancy glucose control, supplementation with multivitamins and fatty acids, and lower glycemic dietary management have been shown to reduce the incidence of birth defects in experimental and epidemiologic studies. However, because more than half of pregnancies are unplanned, these methods are not generalizable across the population. Thus, better interventions are urgently needed. Based on what we know about the molecular pathophysiology of diabetic embryopathy, our laboratory and others are developing interventions against to key molecular targets in this multifactorial disease process.
引用
收藏
页码:24 / 32
页数:9
相关论文
共 50 条
  • [41] Disparities in educational opportunities and outcomes: What do we know and what can we do?
    Maruyama, G
    JOURNAL OF SOCIAL ISSUES, 2003, 59 (03) : 653 - 676
  • [42] The global child labor problem: What do we know and what can we do?
    Basu, K
    Tzannatos, Z
    WORLD BANK ECONOMIC REVIEW, 2003, 17 (02): : 147 - 173
  • [43] The cancer-obesity connection: what do we know and what can we do?
    Riboli, Elio
    BMC BIOLOGY, 2014, 12
  • [44] Tumour budding in colorectal cancer: what do we know and what can we do?
    Linde De Smedt
    Sofie Palmans
    Xavier Sagaert
    Virchows Archiv, 2016, 468 : 397 - 408
  • [45] Tumour budding in colorectal cancer: what do we know and what can we do?
    De Smedt, Linde
    Palmans, Sofie
    Sagaert, Xavier
    VIRCHOWS ARCHIV, 2016, 468 (04) : 397 - 408
  • [46] BRCA1: What do we know? What do we think we know? What do we really need to know?
    Buller, RE
    GYNECOLOGIC ONCOLOGY, 2000, 76 (03) : 291 - 293
  • [47] Medical error: What do we know? What do we do?
    Dwyer, J
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH, 2003, 27 (05) : 564 - 565
  • [48] Keloids: what do we know and what do we do next?
    Blit, Patrick H.
    Jeschke, Marc G.
    TRANSLATIONAL RESEARCH, 2012, 159 (03) : 173 - 174
  • [49] Melanoma overdiagnosis: What do we know and what do we do?
    Clark, Simon
    Rosendahl, Nikita
    Rosendahl, Cliff
    AUSTRALIAN JOURNAL OF GENERAL PRACTICE, 2024, 53 (09) : 612 - 616
  • [50] MENSTRUALLY RELATED DISORDERS - WHAT WE DO KNOW, WHAT WE ONLY BELIEVE THAT WE KNOW, AND WHAT WE KNOW THAT WE DO NOT KNOW
    HALBREICH, U
    CRITICAL REVIEWS IN NEUROBIOLOGY, 1995, 9 (2-3): : 163 - 175